346 results on '"Barlera, Simona"'
Search Results
2. Abstract 16898: Myocardial Recovery Associated Gene Cdcp1 Expression Attenuates Cardiac Fibrosis in a Pressure Over-Load Mouse Model
3. Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease
4. Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis
5. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial
6. A low plasma 1,25(OH)2 vitamin D/PTH (1–84) ratio predicts worsening of renal function in patients with chronic heart failure
7. Red blood cell oleic acid levels reflect olive oil intake while omega-3 levels reflect fish intake and the use of omega-3 acid ethyl esters: The Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico–Heart Failure trial
8. Myocardial Recovery in Recent Onset Dilated Cardiomyopathy: Role of CDCP1 and Cardiac Fibrosis.
9. Cardiac Remodeling, Circulating Biomarkers and Clinical Events in Patients with a History of Atrial Fibrillation. Data from the GISSI-AF Trial
10. Pentraxin 3 in patients with severe sepsis or shock: the ALBIOS trial
11. Laparoscopic cholecystectomy: consensus conference-based guidelines
12. Quantitative Trait Genetic Linkage Analysis of Body Mass Index in Familial Coronary Artery Disease
13. Effects of n-3 polyunsaturated fatty acids on malignant ventricular arrhythmias in patients with chronic heart failure and implantable cardioverter-defibrillators: A substudy of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Insufficienza Cardiaca (GISSI-HF) trial
14. Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico–Atrial Fibrillation (GISSI-AF) trial
15. Improving cardiovascular prevention in general practice: Results of a comprehensive personalized strategy in subjects at high risk
16. Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico–Atrial Fibrillation (GISSI-AF) trial
17. Elevations of inflammatory markers PTX3 and sST2 after resuscitation from cardiac arrest are associated with multiple organ dysfunction syndrome and early death
18. Identification of ZNF366 and PTPRD as novel determinants of plasma homocysteine in a family-based genome-wide association study
19. Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials
20. Circulating cardiac biomarkers and postoperative atrial fibrillation in the OPERA trial
21. Systematic Review and Meta-Analysis: Renin-Angiotensin System Inhibitors in the Prevention of Atrial Fibrillation Recurrences. An Unfulfilled Hope
22. Early Results Indicate Acceptable Safety and Promising Efficacy of Venetoclax in Combination with Pola-R-CHP for Untreated High-Risk BCL-2-Positive B-Cell Lymphoma Including Double/Triple Hit Lymphoma
23. Prognostic Value of Changes in N-Terminal Pro-Brain Natriuretic Peptide in Val-HeFT (Valsartan Heart Failure Trial)
24. Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto (GISSI)–3 trial
25. Genetic variants associated with Lp(a) lipoprotein level and coronary disease
26. ROLE AND FUNCTIONAL CHARACTERIZATION OF CUB-DOMAIN CONTAINING PROTEIN 1 (CDCP1) IN DILATED CARDIOMYOPATHY
27. Neurohormonal modulation in heart failure of ischemic etiology: Correlates with left ventricular remodeling
28. Clinical, Neurohormonal, and Inflammatory Markers and Overall Prognostic Role of Chronic Obstructive Pulmonary Disease in Patients With Heart Failure: Data From the Val-HeFT Heart Failure Trial
29. Appropriate use of antiplatelets: is prescription in daily practice influenced by the global cardiovascular risk?
30. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT)
31. Normalization for peak oxygen uptake increases the prognostic power of the ventilatory response to exercise in patients with chronic heart failure
32. Autonomic markers and cardiovascular and arrhythmic events in heart failure patients: still a place in prognostication? Data from the GISSI-HF trial
33. The Prognostic Value of Big Endothelin-1 in More Than 2,300 Patients With Heart Failure Enrolled in the Valsartan Heart Failure Trial (Val-HeFT)
34. Are Myocardial Infarction–Associated Single-Nucleotide Polymorphisms Associated With Ischemic Stroke?
35. Incidence and short-term prognosis of late sustained ventricular tachycardia after myocardial infarction: results of the Gruppo Italiano per lo Studio della Sopravvivenza nell-Infarto Miocardico (GISSI-3) data base
36. Adiponectin in chronic heart failure: influence of diabetes and genetic variants
37. Predicting atrial fibrillation recurrence with circulating inflammatory markers in patients in sinus rhythm at high risk for atrial fibrillation: data from the GISSI atrial fibrillation trial
38. Prognostic significance of double product and inadequate double product response to maximal symptom-limited exercise stress testing after myocardial infarction in 6,296 patients treated with thrombolytic agents
39. Effect of n-3 polyunsaturated fatty acids and rosuvastatin in patients with heart failure: results of the GISSI-HF trial
40. Anemia in Patients With Heart Failure: Prevalence and Prognostic Role in a Controlled Trial and in Clinical Practice
41. Thrombolysis or nothing for acute myocardial infarction? Itʼs all the same!
42. Causes of death in patients with acute myocardial infarction treated with angiotensin-converting enzyme inhibitors: Findings from the Gruppo Italiano per lo Studio della Sopravvivenza nellʼ Infarto (GISSI)-3 trial
43. Apolipoprotein E polymorphisms influence effect of pravastatin on survival after myocardial infarction in a Mediterranean population: the GISSI-Prevenzione study
44. Administration of thrombolytic therapy to 17,944 patients with acute myocardial infarction: the GISSI-3 database
45. Severity of left ventricular remodeling defines outcomes and response to therapy in heart failure: Valsartan heart failure trial (Val-HeFT) echocardiographic data
46. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT
47. Lung Function and Methacholine Responsiveness among Adolescents in an Air-Polluted Area
48. Quality Assessment and Quality Control of Echocardiographic Performance in a Large Multicenter International Study: Valsartan in Heart Failure Trial (Val-HeFT)
49. Incidence and short-term prognosis of late sustained ventricular tachycardia after myocardial infarction: Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI-3) Data Base
50. Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.